All News
No Great Options for Treating VEXAS
d
MedPage Today
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
Read Article
The Window of Opportunity (5.24.2024)
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Read Article
Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis
A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.
Lupus Research Alliance Grants for Lupus Innovation
d
EurekAlert!
The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA).
Read Article
Window of Opportunity in Psoriatic Arthritis
The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome.
Small-molecule Drugs to Treat Systemic Lupus Erythematosus
A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs.
https://t.co/LKLUT8kLSk https://t.co/1SbUbiCpYs
Dr. John Cush RheumNow ( View Tweet)
Window of Opportunity in Psoriatic Arthritis
The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome.
https://t.co/eUL1wzrXVt https://t.co/XSETW2zpGs
Dr. John Cush RheumNow ( View Tweet)
Research presented at DDW 2024 demonstrated the superiority of guselkumab over ustekinumab or placebo in 1,021 patients with moderately to severely active Crohn's disease enrolled in the phase III GALAXI 2 and GALAXI 3 trials https://t.co/HdZf24Twsq https://t.co/REeAAskpX5
Dr. John Cush RheumNow ( View Tweet)
DRESS - Drug Reaction With Eosinophilia and Systemic Symptoms - review on JAMA. Common drugs include allopurinol, Bactrim, Minocin, etc. https://t.co/1DmgyX33Cl
Dr. John Cush RheumNow ( View Tweet)
No Link Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance
Annals of Internal Medicine reports a study of more than 75,000 persons screened for MGUS and found no association between AIRD and MGUS.
https://t.co/cTuIWU7eoa https://t.co/78kQvBGVzs
Dr. John Cush RheumNow ( View Tweet)
SLE Cost of Care and Disease Activity
A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity.
https://t.co/Rk7SNpHaKu https://t.co/yvJ4qw1YCJ
Dr. John Cush RheumNow ( View Tweet)
Lille Univ Hosp study of 485 systemic sclerosis pts, found osteoporosis in 23% (18% w/ fragility Fx). OP independently linked to age (OR1.06), topoisomerase I Ab+ positivity (OR 2.22) & GC treatment (OR 4.48) https://t.co/9KN5VQnl4A https://t.co/L7RwDdzaFZ
Dr. John Cush RheumNow ( View Tweet)
Greek cohort study of 570 SLE pts; lupus nephritis was initial presentation in 59, w/ another 66 LN during F/U (total LN= 22%). Predictors of LN: male sex (adjHR 4.31), Dx age <26yrs (3.71), Hi dsDNA (2.48), low C3/C4 (NS 2.24) https://t.co/lGmZlBpaPq https://t.co/XLqODDTnX6
Dr. John Cush RheumNow ( View Tweet)
"Don't You Know Who I am?" (5.17.2024)
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?
https://t.co/oH5qdTvGY9 https://t.co/gTqIKemvOu
Dr. John Cush RheumNow ( View Tweet)
Australian multicenter KARAOKE RCT of 262 adults w/ Knee OA (w/ MRI effusion/synovitis) Rx w/ placebo vs , 2 g/d of krill oil showed no significant benefit in pain VAS score, −19.9 [krill oil] vs −20.2 [placebo]. https://t.co/8QSZyzIVh9 https://t.co/WbSb2gcmHb
Dr. John Cush RheumNow ( View Tweet)
Upside/Downside of Steroids in Lupus Nephritis
A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes.
https://t.co/6NR3obURAw https://t.co/YyYBg1TcYr
Dr. John Cush RheumNow ( View Tweet)
Disparities in SLE care: adult Medicare cohort study of 1,036 SLE pts found 39% saw a rheumatologist q 6 mos & 28% had serologic tests. Least disadvantaged quintile had higher visit-based retention, but decreased serologic testing (aOR 0.80) https://t.co/lGoriPIMqV https://t.co/JF0RWZxRoU
Dr. John Cush RheumNow ( View Tweet)
Best Selling US Drugs in 2023
11 Skyrizi $10.1 billion
10 Dupixent $11.5 b
9 Biktarvy $13.15 b
8 Mounjaro $13.16 b
7 Keytruda $15.4 b
6 Stelara $15.87 b
5 Jardiance $15.89 b
4 Trulicity $16.3 b
3 Eliquis $22.1 b
2 Humira $35.3 b
1 Ozempic $38.6 b https://t.co/tiEwqyTB6D https://t.co/xghijiRFtW
Dr. John Cush RheumNow ( View Tweet)
384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical PsA) & 9.4% got PsA within 12 mos (23% by 36%). Subclinical more likely than PSO to get PsA (OR 11.7) https://t.co/D7n3ZpJURH https://t.co/vJcFgRcbx4
Dr. John Cush RheumNow ( View Tweet)
NON-treatment of 18,318 VA pts (RA, SpA, PsA) = 41% not Rx DMARDs w/in 12 mos of Dx. Signif higher odds if Black (HR 1.13), Hispanic (1.14), Charlson Comorbidity ≥2 (1.15), opiate use (1.09). DMARD use ^ if married, w/ erosions, female MD, Rheum Dx https://t.co/TaYC27oIOz https://t.co/qjfAGI5L5g
Links:
Dr. John Cush RheumNow ( View Tweet)